(PDF) Assessing Variation in the Cost of Palivizumab for

Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants

PharmacoEconomics - Open - Switzerland

doi 10.1007/s41669-017-0042-3

Full Text

Abstract

Available in full text

Categories

Date

July 17, 2017

Authors

Kimmie McLaurin

Publisher

Springer Science and Business Media LLC

Related search

Respiratory Syncytial Virus (RSV) Immune Globulin and Palivizumab for Prevention of RSV Infection

American Journal of Health-System Pharmacy

English

Hospital Admission of High Risk Infants for Respiratory Syncytial Virus Infection: Implications for Palivizumab Prophylaxis

Archives of Disease in Childhood: Fetal and Neonatal Edition

English

Correction To: Cost-Effectiveness of Rule-Based Immunoprophylaxis Against Respiratory Syncytial Virus Infections in Preterm Infants

European Journal of Pediatrics

English

Appropriateness of Age Thresholds for Respiratory Syncytial Virus Immunoprophylaxis in Moderate-Preterm Infants

JAMA Pediatrics

English

The Effect of Palivizumab Prophylaxis on Respiratory Syncytial Virus-Associated Hospitalizations in Infants With Congenital Diaphragmatic Hernia

Pediatrics and Neonatology

English

Chronologic Age at Hospitalization for Respiratory Syncytial Virus Among Preterm and Term Infants in the United States

Infectious Diseases and Therapy

Infectious Diseases

English

Viral Load in Respiratory Syncytial Virus Infected Premature Newborns Under Prophylaxis With Palivizumab

Virology: Research and Reviews

English

4cps-069 Evaluation of Palivizumab as Prophylaxis Against Respiratory Syncytial Virus Infection

English

770 Pathogenesis of Respiratory Syncytial (Rs) Virus Bronchiolitis in Infants

Pediatric Research

English